Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 11/20 | 0.52 |
| ▸ | IDO1 | P14902 | 2/20 | 0.38 |
| ▸ | AGXT | P21549 | 2/20 | 0.38 |
| ▸ | MAOB | P27338 | 2/20 | 0.36 |
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
| ▸ | APP | P05067 | 3/20 | 0.35 |
| ▸ | CTSL | P07711 | 1/20 | 0.35 |
| ▸ | CTSB | P07858 | 1/20 | 0.35 |
| ▸ | CTSK | P43235 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14734276 | 0.90 | NAAA (0.48) | NAAAIDO1AGXTMAOBMAOA | |
| SCHEMBL3055323 | 0.76 | NAAA (0.50) | NAAAIDO1AGXT | |
| SCHEMBL15883399 | 0.76 | NAAA (0.50) | NAAAIDO1AGXT | |
| SCHEMBL27034936 | 0.74 | NAAA (0.47) | NAAACTSLCTSBCTSK | |
| SCHEMBL3049685 | 0.73 | NAAA (0.58) | NAAAIDO1AGXTAPPCTSL | |
| SCHEMBL14734277 | 0.70 | NAAA (0.46) | NAAAIDO1AGXT | |
| SCHEMBL18615761 | 0.70 | NAAA (0.54) | NAAAIDO1AGXTMAOBAPP | |
| SCHEMBL16654046 | 0.70 | NAAA (0.54) | NAAAIDO1AGXTMAOBAPP | |
| SCHEMBL14734271 | 0.69 | NAAA (0.54) | NAAAIDO1AGXT | |
| SCHEMBL17274389 | 0.69 | NAAA (1.00) | NAAACTSLCTSBCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2747769-B1 | 2-SPIRO-SUBSTITUTED IMINOTHIAZINES AND THEIR MONO-AND DIOXIDES AS BACE INHIBITORS, COMPOSITIONS AND THEIR USE | MERCK SHARP & DOHME (US) | 2017-08-02 | — | — | EP | disclosed |
| US-9181236-B2 | 2-spiro-substituted iminothiazines and their mono-and dioxides as bace inhibitors, compositions and their use | MERCK SHARP & DOHME CORP. (US) | 2015-11-10 | — | — | US | disclosed |
| US-20140200213-A1 | 2-SPIRO-SUBSTITUTED IMINOTHIAZINES AND THEIR MONO-AND DIOXIDES AS BACE INHIBITORS, COMPOSITIONS AND THEIR USE | MERCK SHARP & DOHME CORP. (US) | 2014-07-17 | — | — | US | disclosed |
| WO-2013028670-A1 | 2-SPIRO-SUBSTITUTED IMINOTHIAZINES AND THEIR MONO-AND DIOXIDES AS BACE INHIBITORS, COMPOSITIONS AND THEIR USE | MERCK SHARP & DOHME CORP. (US) | 2013-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140200213-A1 | 2-SPIRO-SUBSTITUTED IMINOTHIAZINES AND THEIR MONO-AND DIOXIDES AS BACE INHIBITORS, COMPOSITIONS AND THEIR USE | BACE2, BACE1, APP | NAAA 3935/4885IDO1 979/4885AGXT 3281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.